Literature DB >> 12677558

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

A Antoniou1, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg, B Pasini, P Radice, S Manoukian, D M Eccles, N Tang, E Olah, H Anton-Culver, E Warner, J Lubinski, J Gronwald, B Gorski, H Tulinius, S Thorlacius, H Eerola, H Nevanlinna, K Syrjäkoski, O-P Kallioniemi, D Thompson, C Evans, J Peto, F Lalloo, D G Evans, D F Easton.   

Abstract

Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer, but the average magnitude of these risks is uncertain and may depend on the context. Estimates based on multiple-case families may be enriched for mutations of higher risk and/or other familial risk factors, whereas risk estimates from studies based on cases unselected for family history have been imprecise. We pooled pedigree data from 22 studies involving 8,139 index case patients unselected for family history with female (86%) or male (2%) breast cancer or epithelial ovarian cancer (12%), 500 of whom had been found to carry a germline mutation in BRCA1 or BRCA2. Breast and ovarian cancer incidence rates for mutation carriers were estimated using a modified segregation analysis, based on the occurrence of these cancers in the relatives of mutation-carrying index case patients. The average cumulative risks in BRCA1-mutation carriers by age 70 years were 65% (95% confidence interval 44%-78%) for breast cancer and 39% (18%-54%) for ovarian cancer. The corresponding estimates for BRCA2 were 45% (31%-56%) and 11% (2.4%-19%). Relative risks of breast cancer declined significantly with age for BRCA1-mutation carriers (P trend.0012) but not for BRCA2-mutation carriers. Risks in carriers were higher when based on index breast cancer cases diagnosed at <35 years of age. We found some evidence for a reduction in risk in women from earlier birth cohorts and for variation in risk by mutation position for both genes. The pattern of cancer risks was similar to those found in multiple-case families, but their absolute magnitudes were lower, particularly for BRCA2. The variation in risk by age at diagnosis of index case is consistent with the effects of other genes modifying cancer risk in carriers.

Entities:  

Mesh:

Year:  2003        PMID: 12677558      PMCID: PMC1180265          DOI: 10.1086/375033

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  43 in total

1.  Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group.

Authors:  D F Easton; J Peto; A G Babiker
Journal:  Stat Med       Date:  1991-07       Impact factor: 2.373

2.  Programs for Pedigree Analysis: MENDEL, FISHER, and dGENE.

Authors:  K Lange; D Weeks; M Boehnke
Journal:  Genet Epidemiol       Date:  1988       Impact factor: 2.135

3.  Identification of the breast cancer susceptibility gene BRCA2.

Authors:  R Wooster; G Bignell; J Lancaster; S Swift; S Seal; J Mangion; N Collins; S Gregory; C Gumbs; G Micklem
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

4.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

5.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.

Authors:  D F Easton; D T Bishop; D Ford; G P Crockford
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

6.  Genetic epidemiology of early onset breast cancer.

Authors:  D Eccles; A Marlow; G Royle; A Collins; N E Morton
Journal:  J Med Genet       Date:  1994-12       Impact factor: 6.318

7.  Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus.

Authors:  C M Phelan; T R Rebbeck; B L Weber; P Devilee; M H Ruttledge; H T Lynch; G M Lenoir; M R Stratton; D F Easton; B A Ponder; L Cannon-Albright; C Larsson; D E Goldgar; S A Narod
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

8.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

9.  Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; D T Bishop; S A Narod; D E Goldgar
Journal:  Lancet       Date:  1994-03-19       Impact factor: 79.321

10.  Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation.

Authors:  S A Gayther; W Warren; S Mazoyer; P A Russell; P A Harrington; M Chiano; S Seal; R Hamoudi; E J van Rensburg; A M Dunning; R Love; G Evans; D Easton; D Clayton; M R Stratton; B A Ponder
Journal:  Nat Genet       Date:  1995-12       Impact factor: 38.330

View more
  1056 in total

Review 1.  The inherited genetics of ovarian and endometrial cancer.

Authors:  Simon A Gayther; Paul D P Pharoah
Journal:  Curr Opin Genet Dev       Date:  2010-04-24       Impact factor: 5.578

2.  No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families.

Authors:  Larissa A Korde; Christine M Mueller; Jennifer T Loud; Jeffery P Struewing; Kathy Nichols; Mark H Greene; Phuong L Mai
Journal:  Breast Cancer Res Treat       Date:  2010-05-11       Impact factor: 4.872

Review 3.  Hereditary breast and ovarian cancer: new genes, new treatments, new concepts.

Authors:  Alfons Meindl; Nina Ditsch; Karin Kast; Kerstin Rhiem; Rita K Schmutzler
Journal:  Dtsch Arztebl Int       Date:  2011-05-13       Impact factor: 5.594

Review 4.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

5.  Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis.

Authors:  Kathryn P Lowry; Janie M Lee; Chung Y Kong; Pamela M McMahon; Michael E Gilmore; Jessica E Cott Chubiz; Etta D Pisano; Constantine Gatsonis; Paula D Ryan; Elissa M Ozanne; G Scott Gazelle
Journal:  Cancer       Date:  2011-09-20       Impact factor: 6.860

6.  Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.

Authors:  Pascal Pujol; Christine Lasset; Pascaline Berthet; Catherine Dugast; Suzette Delaloge; Jean-Pierre Fricker; Isabelle Tennevet; Nathalie Chabbert-Buffet; Pascale This; Karen Baudry; Jerome Lemonnier; Lise Roca; Sylvie Mijonnet; Paul Gesta; Jean Chiesa; Helene Dreyfus; Philippe Vennin; Capucine Delnatte; Yves Jean Bignon; Alain Lortholary; Fabienne Prieur; Laurence Gladieff; Anne Lesur; Krishna B Clough; Catherine Nogues; Anne-Laure Martin
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

7.  Returning a Genomic Result for an Adult-Onset Condition to the Parents of a Newborn: Insights From the BabySeq Project.

Authors:  Ingrid A Holm; Amy McGuire; Stacey Pereira; Heidi Rehm; Robert C Green; Alan H Beggs
Journal:  Pediatrics       Date:  2019-01       Impact factor: 7.124

Review 8.  Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.

Authors:  Tuya Pal; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

9.  Testing for the recurrent HOXB13 G84E germline mutation in men with clinical indications for prostate biopsy.

Authors:  Florian R Schroeck; Kimberly A Zuhlke; Javed Siddiqui; Rabia Siddiqui; Kathleen A Cooney; John T Wei
Journal:  J Urol       Date:  2012-10-02       Impact factor: 7.450

Review 10.  Management updates for women with a BRCA1 or BRCA2 mutation.

Authors:  Rachel Nusbaum; Claudine Isaacs
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.